Microbix Biosystems (TSX:MBX) FCF Margin %: -15.72% (As of Mar. 2026)

What is Microbix Biosystems FCF Margin %?

Microbix Biosystems TSX:MBX +5.17% 52 FCF Margin % is -15.72% as of Mar. 2026. GuruFocus rates TSX:MBX with a GF Score™ of 52/100 and a GF Value™ of C$0.24 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 959 Biotechnology companies, Microbix Biosystems ranks better than 58.19% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Microbix Biosystems's Free Cash Flow for the three months ended in Mar. 2026 was C$-0.53 Mil. Microbix Biosystems's Revenue for the three months ended in Mar. 2026 was C$3.38 Mil. Therefore, Microbix Biosystems's FCF Margin % for the quarter that ended in Mar. 2026 was -15.72%.

As of today, Microbix Biosystems's current FCF Yield % is -13.10%.

The historical rank and industry rank for Microbix Biosystems's FCF Margin % or its related term are showing as below:

TSX:MBX' s FCF Margin % Range Over the Past 10 Years
Min: -37.08 Med: -4.12 Max: 9.61
Current: -37.08

During the past 13 years, the highest FCF Margin % of Microbix Biosystems was 9.61%. The lowest was -37.08%. And the median was -4.12%.

TSX:MBX's FCF Margin % is ranked better than
58.19% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs TSX:MBX: -37.08

Microbix Biosystems FCF Margin % Related Terms

Microbix Biosystems FCF Margin % Historical Data

* Premium members only.

The historical data trend for Microbix Biosystems's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbix Biosystems FCF Margin % Chart

Microbix Biosystems Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

FCF Margin %

Get a 7-Day Free Trial

4.32

7.54

-12.78

9.61

-4.72

Microbix Biosystems Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															14.07	-61.03	-1.87	-65.70	-15.72

TSX:MBX vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Microbix Biosystems's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microbix Biosystems FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's FCF Margin % falls into.

Save Embed

52GF Score

Microbix Biosystems Inc TSX:MBX

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Microbix Biosystems FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Microbix Biosystems's FCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2025 )	/	Revenue (A: Sep. 2025 )
	=	-0.877	/	18.585
	=	-4.72 %

Microbix Biosystems's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-0.531	/	3.378
	=	-15.72 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -15.72% mean?

Microbix Biosystems (TSX:MBX) has a FCF Margin % of -15.72% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Microbix Biosystems and its competitors. According to the industry distribution chart, Microbix Biosystems ranks #401 out of 959 companies in the Biotechnology industry, placing it in the top 41.8%.

Is Microbix Biosystems' FCF Margin % too high?

Microbix Biosystems' current FCF Margin % is -15.72%. Based on the distribution chart, Microbix Biosystems ranks #401 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Microbix Biosystems has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Microbix Biosystems' FCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #401 out of 959 companies for FCF Margin %. This puts Microbix Biosystems in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current FCF Margin % is -15.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Microbix Biosystems stock overvalued right now?

Based on GuruFocus' analysis, Microbix Biosystems (TSX:MBX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.24, compared to a current price of C$0.31 — trading 27.1% above its estimated fair value. The current FCF Margin % is -15.72%. Microbix Biosystems' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Microbix Biosystems (TSX:MBX), the current FCF Margin % is -15.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microbix Biosystems (TSX:MBX) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of C$0.31 is trading 27.1% above its estimated GF Value™ of C$0.24. GuruFocus considers Microbix Biosystems to be Modestly Overvalued.

Key valuation signals for TSX:MBX:

FCF Margin %: -15.72%
GF Value™: C$0.24 vs. price of C$0.31 (27.1% above fair value)
GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the TSX:MBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microbix Biosystems Business Description

Industry Healthcare Biotechnology

Comparable Companies TSX:BCT TSX:MDNA TSXV:MIR TSXV:TTI TSXV:GSD XCNQ:DTC TSXV:ARCH TSX:RVX XCNQ:LOBE TSX:SVA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges MBXBF:USA

Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3

Website https://www.microbix.com

Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.

52GF Score

Get the complete analysis for TSX:MBX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.31

Price

C$0.24

GF Value

View TSX:MBX Analysis

See FCF Margin % data for all stocks →